Market Overview

BioCryst Pharmaceuticals, Presidio Pharmaceuticals Terminate Merger Agreement


BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and privately held Presidio
Pharmaceuticals, Inc. today announced the mutual termination of the
Merger Agreement and the related Investor Financing Agreement entered
into on October 17, 2012. Although the original rationale for the merger
had merit, the parties determined that terminating the merger was in the
best interest of both companies and their respective shareholders at
this time.

The termination of the transaction has been approved by the Boards of
both companies. In association with the termination, both parties will
release each other from all obligations with respect to the proposed
transaction. Each company will bear its own legal and transaction fees.

See full press release

Posted-In: M&A News Guidance Management


Related Articles (BCRX)

View Comments and Join the Discussion!

Nexstar Prices 8M Share Secondary Offering at $9.25/Share

Pacific Premier Bancorp Receives Regulatory Approval to Acquire First Associations Bank